Drug Interactions of Newer Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban with Routinely Used Nonanticoagulant/Antiplatelet Drugs

被引：0
|
作者：
Sayani, Shermin [1 ]
Iqbal, Omer [1 ]
Hoppensteadt, Debra [1 ]
Fareed, Jawed [1 ]
机构：
[1] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 48 条
  • [1] Drug interactions of newer oral anticoagulants dabigatran, rivaroxaban, and apixaban with routinely used nonanticoagulant/antiplatelet drugs
    Sayani, S.
    Iqbal, O.
    Hoppensteadt, D.
    Fareed, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 897 - 897
  • [2] Novel Oral Anticoagulants in Development: Dabigatran, Rivaroxaban, and Apixaban
    Sattari, Maryam
    Lowenthal, David T.
    AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (04) : 332 - 338
  • [3] EFFICACY AND SAFETY OF THE NOVEL ORAL ANTICOAGULANTS DABIGATRAN, RIVAROXABAN AND APIXABAN
    Elnadoury, Ola
    Yuen, Meggie
    Oh, Erin
    Abraham, Teena
    Saad, Nasser
    CRITICAL CARE MEDICINE, 2014, 42 (12)
  • [4] Laboratory Monitoring of Newer Oral Anticoagulants, Rivaroxaban, Apixaban and Dabigatran: Do We Have an Adequate Test?
    Hoppensteadt, Debra
    Walenga, Jeanine M.
    Cunanan, Josephine
    Iqbal, Omer
    Lewis, Bruce
    Kalodiki, Evi
    Kahn, Stephen
    Fareed, Jawed
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 : S178 - S178
  • [5] Selection of a Suitable Rapid Turn Around and Sensitive Test for the Laboratory Monitoring of Newer Oral Anticoagulants, Rivaroxaban, Apixaban and Dabigatran
    Hoppensteadt, Debra
    Walenga, Jeanine M.
    Cunanan, Josephine
    Iqbal, Omer
    Lewis, Bruce E.
    Kalodiki, Evi
    Kahn, Stephen
    Fareed, Jawed
    BLOOD, 2011, 118 (21) : 1442 - 1443
  • [6] The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban)
    O'connor, Cormac T.
    Kiernan, Thomas J.
    Yan, Bryan P.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (07) : 725 - 739
  • [7] Direct oral anticoagulants (DOACs) - dabigatran, rivaroxaban, apixaban, edoxaban - addition - EML
    SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN), 2019, 1021 : 339 - 355
  • [8] Different Involvement of OAT in Renal Disposition of Oral Anticoagulants Rivaroxaban, Dabigatran, and Apixaban
    Tsuruya, Yuri
    Nakanishi, Takeo
    Komori, Hisakazu
    Wang, Xinying
    Ishiguro, Naoki
    Kito, Tomoko
    Ikukawa, Kouji
    Kishimoto, Wataru
    Ito, Sumito
    Schaefer, Olaf
    Ebner, Thomas
    Yamamura, Norio
    Kusuhara, Hiroyuki
    Tamai, Ikumi
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (09) : 2524 - 2534
  • [9] Emergency surgery and trauma in patients treated with the new oral anticoagulants: Dabigatran, rivaroxaban, and apixaban
    Moorman, Matthew L.
    Nash, Joshua E.
    Stabi, Katie L.
    JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2014, 77 (03): : 486 - 494
  • [10] New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future
    Dumont, Benedicte
    Faille, Dorothee
    Ajzenberg, Nadine
    M S-MEDECINE SCIENCES, 2011, 27 (05): : 493 - 500
12345